Table 4. Comparison of sensitivity and specificity between Framingham and 10-year ASCVD risk scoring system for alignment of statin therapy in subjects with subclinical coronary atherosclerosis.

MDCT findings	Framingham risk scoring				2013 ASCVD risk scoring				P value
	Cut off	Sensitivity	Specificity	AUC (95% CI)	Cut off	Sensitivity	Specificity	AUC (95% CI)	(2004 vs. 2013)
Significant stenosis	6	70.6	63.3	0.71 (0.69–0.72)	5.85	70.6	66.8	0.73 (0.72–0.74)	.025
CACS>0	5	71.3	61.2	0.72 (0.71–0.73)	4.25	74.4	62.1	0.75 (0.73–0.76)	.027
CACS>100	5	78.4	53.5	0.70 (0.69–0.71)	4.86	77.3	59.6	0.74 (0.73–0.76)	.044
Any plaque	5	69.3	63.4	0.72 (0.71–0.73)	4.26	71.3	64.1	0.74 (0.73–0.76)	.024
CAP	4	79.0	49.7	0.69 (0.68–0.71)	3.85	78.5	54.2	0.73 (0.71–0.74)	.032
NCAP	5	70.0	55.3	0.67 (0.66–0.68)	5.16	62.9	63.7	0.68 (0.67–0.69)	.012
MCAP	6	71.1	63.7	0.72 (0.71–0.73)	6.47	66.3	71.2	0.74 (0.73–0.75)	.022

ASCVD, atherosclerotic cardiovascular disease; AUC, areas under the curve; CACS, coronary artery calcium scores; CAP, calcified plaque; NCAP, noncalcified plaque; MCAP, mixed plaque.